New diploma to shed light on market access
This article was originally published in Scrip
Gaining market access for pharmaceuticals is a new hurdle in drug development, so much so that the University of Lyon and the Ecole Pratique des Hautes Etudes of Sorbonne-Paris have set up the European Market Access University Diploma (EMAUD).
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.